416 related articles for article (PubMed ID: 34953399)
1. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers.
Palmeri M; Mehnert J; Silk AW; Jabbour SK; Ganesan S; Popli P; Riedlinger G; Stephenson R; de Meritens AB; Leiser A; Mayer T; Chan N; Spencer K; Girda E; Malhotra J; Chan T; Subbiah V; Groisberg R
ESMO Open; 2022 Feb; 7(1):100336. PubMed ID: 34953399
[TBL] [Abstract][Full Text] [Related]
2. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors.
Cristescu R; Aurora-Garg D; Albright A; Xu L; Liu XQ; Loboda A; Lang L; Jin F; Rubin EH; Snyder A; Lunceford J
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101941
[TBL] [Abstract][Full Text] [Related]
3. Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.
Schrock AB; Ouyang C; Sandhu J; Sokol E; Jin D; Ross JS; Miller VA; Lim D; Amanam I; Chao J; Catenacci D; Cho M; Braiteh F; Klempner SJ; Ali SM; Fakih M
Ann Oncol; 2019 Jul; 30(7):1096-1103. PubMed ID: 31038663
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Lee KW; Van Cutsem E; Bang YJ; Fuchs CS; Kudaba I; Garrido M; Chung HC; Lee J; Castro HR; Chao J; Wainberg ZA; Cao ZA; Aurora-Garg D; Kobie J; Cristescu R; Bhagia P; Shah S; Tabernero J; Shitara K; Wyrwicz L
Clin Cancer Res; 2022 Aug; 28(16):3489-3498. PubMed ID: 35657979
[TBL] [Abstract][Full Text] [Related]
5. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
6. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
[TBL] [Abstract][Full Text] [Related]
7. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
[TBL] [Abstract][Full Text] [Related]
8. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
[TBL] [Abstract][Full Text] [Related]
9. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden.
Florou V; Floudas CS; Maoz A; Naqash AR; Norton C; Tan AC; Sokol ES; Frampton G; Soares HP; Puri S; Swami U; Wilky B; Hosein P; Trent J; Lopes GL; Park W; Garrido-Laguna I
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586768
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy in Patients With Metastatic Colorectal Cancer With Measures of Microsatellite Instability, Mismatch Repair, or Tumor Mutational Burden.
Quintanilha JCF; Graf RP; Fisher VA; Oxnard GR; Ellis H; Panarelli N; Lin DI; Li G; Huang RSP; Ross JS; Myer PA; Klempner SJ
JAMA Netw Open; 2023 Jan; 6(1):e2252244. PubMed ID: 36689222
[TBL] [Abstract][Full Text] [Related]
11. Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors.
Salem ME; Bodor JN; Puccini A; Xiu J; Goldberg RM; Grothey A; Korn WM; Shields AF; Worrilow WM; Kim ES; Lenz HJ; Marshall JL; Hall MJ
Int J Cancer; 2020 Nov; 147(10):2948-2956. PubMed ID: 32449172
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite-Stable Tumors with High Mutational Burden Benefit from Immunotherapy.
Goodman AM; Sokol ES; Frampton GM; Lippman SM; Kurzrock R
Cancer Immunol Res; 2019 Oct; 7(10):1570-1573. PubMed ID: 31405947
[TBL] [Abstract][Full Text] [Related]
13. Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer.
Wang Z; Zhang Q; Qi C; Bai Y; Zhao F; Chen H; Li Z; Wang X; Chen M; Gong J; Peng Z; Zhang X; Cai J; Chen S; Zhao X; Shen L; Li J
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705314
[TBL] [Abstract][Full Text] [Related]
14. Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD-L1 expression in cancer patients.
Nikanjam M; Arguello D; Gatalica Z; Swensen J; Barkauskas DA; Kurzrock R
Int J Cancer; 2020 Jun; 146(11):3087-3097. PubMed ID: 31479512
[TBL] [Abstract][Full Text] [Related]
15. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
16. Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study.
Antoniotti C; Korn WM; Marmorino F; Rossini D; Lonardi S; Masi G; Randon G; Conca V; Boccaccino A; Tomasello G; Passardi A; Swensen J; Ugolini C; Oberley M; Tamburini E; Casagrande M; Domenyuk V; Fontanini G; Giordano M; Abraham J; Spetzler D; Falcone A; Lenz HJ; Cremolini C
Eur J Cancer; 2021 Sep; 155():73-84. PubMed ID: 34365081
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
18. A real-world experience of pembrolizumab monotherapy in microsatellite instability-high and/or tumor mutation burden-high metastatic castration-resistant prostate cancer: outcome analysis.
Mosalem O; Tan W; Bryce AH; Dronca RS; Childs DS; Pagliaro LC; Orme JJ; Kase AM
Prostate Cancer Prostatic Dis; 2024 Feb; ():. PubMed ID: 38341460
[TBL] [Abstract][Full Text] [Related]
19. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
Vanderwalde A; Spetzler D; Xiao N; Gatalica Z; Marshall J
Cancer Med; 2018 Mar; 7(3):746-756. PubMed ID: 29436178
[TBL] [Abstract][Full Text] [Related]
20. Genomic characterization and immunotherapy for microsatellite instability-high in cholangiocarcinoma.
Yang X; Lian B; Zhang N; Long J; Li Y; Xue J; Chen X; Wang Y; Wang Y; Xun Z; Piao M; Zhu C; Wang S; Sun H; Song Z; Lu L; Dong X; Wang A; Liu W; Pan J; Hou X; Guan M; Huo L; Shi J; Zhang H; Zhou J; Lu Z; Mao Y; Sang X; Wu L; Yang X; Wang K; Zhao H
BMC Med; 2024 Jan; 22(1):42. PubMed ID: 38281914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
